Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Meta Expands AI Training With Employee Activity Tracking Tools 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
MONTPELLIER, France, Feb. 26, 2016 -- MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, is pleased to announce the first surgical operation with the ROSA™ robotic surgery system in Australia.
The stereoelectroencephalography (SEEG) procedure, assisted by the ROSA™ Brain system, was used to treat a patient with epilepsy, by precisely implanting electrodes in the brain to determine the area most likely to be responsible for seizures. The procedure was performed by Dr. Jason Papacostas at Mater Hospital in Brisbane, on a 47 year-old patient with drug-resistant epilepsy.
Mater Hospital in Brisbane is a leading healthcare center and initiates innovative programs to improve patient care management. It is an active participant in the National Demonstration Hospitals Program.
“Today, epilepsy affects up to 90,000 families in the state of Queensland,” said Dr. Papacostas. “Many patients do not respond to medical treatment, so surgery is their best option. ROSA™ represents a medical breakthrough for neurosurgeons and their patients, by considerably reducing surgery time in SEEG procedures - around two hours with ROSA™, compared to six hours with the traditional approach - and providing greater safety and efficiency.”
“We are proud to be part of this great clinical success, achieved for the first time in the southern hemisphere. The treatment of epilepsy has been a significant driver of ROSA™ adoption in the United States and Europe and we believe this will contribute to the ongoing spread of our technology, to the benefit of treatment for this disease affecting at least 50 million people worldwide,” said Bertin Nahum, CEO and founder of Medtech.
About MEDTECH
Founded in 2002 by Bertin NAHUM and based in Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.
In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.
In 2013 MEDTECH received the “European Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.
In October 2014, MEDTECH won the “Révélation” prize in the Mediterranean Deloitte Technology Fast 50 Awards.
In 2015 MEDTECH received the “2016 Company of the Year Award” in the “robotic neurosurgery” category from Frost & Sullivan.
In November 2015, MEDTECH was honored by Deloitte In Extenso for its excellent performance in the Technology Fast 50 Mediterranean Awards, in the “listed company” category.
In January 2016, MEDTECH obtained the FDA clearance for its new product, ROSA™ Spine, a robotic-assistive device for minimally invasive surgery of the spine.
CONTACT MEDTECH Christophe Sibillin Chief Financial Officer Tel : +33 (0)4 67 10 77 40 INVESTORS Corinne Puissant Tel : +33 (0)1 53 67 36 77 [email protected] PRESS Alexandra Prisa (EU) Tel. : +33(0)1 53 67 36 90 [email protected] Joanna Zimmerman (US) Tel : +1 646-536-7006 [email protected]
